Innovative therapeutic solutions to treat respiratory virus infections
We are exploiting a newly discovered and proprietary technology platform that blocks the multiplication of many viruses.
WE ARE COMMITTED TO
providing innovative and much-needed therapeutic solutions to solve clinical challenges, reduce healthcare and economic burdens caused by virus infections and improve patient life quality.
What make us different
Innovative technology
Our technology platform targets and interrupts conserved protein-protein interactions that are essential for the multiplication of a family of related viruses.
Broad spectrum capabilities
By inhibiting specific and conserved protein-protein interactions required for virus multiplication, we can create effective therapeutics to treat several related infections.
Impressive results
Our proof of concept research demonstrated that our innovative strategy to block virus multiplication is highly effective.
Have questions? you can ask here
This project has received funding from the European Union’s Horizon 2020 SME Instrument Phase I programme under grant agreement number 856226.